5-Hydroxytryptophan / Dose Cancer Research Results

5-HTP, 5-Hydroxytryptophan: Click to Expand ⟱
Features:
5-HTP (5-Hydroxytryptophan) is a naturally occurring amino acid and chemical precursor in the biosynthesis of serotonin(5-HT).

5-HTP — 5-Hydroxytryptophan (L-5-HTP) is an endogenous amino-acid intermediate in tryptophan metabolism and the immediate biochemical precursor to serotonin (5-HT) and downstream melatonin. It is most commonly used as an orally administered dietary supplement (often derived from Griffonia simplicifolia seed extracts) rather than as a regulated drug product; common abbreviations include 5-HTP and L-5-HTP. In humans it is rapidly converted by aromatic L-amino-acid decarboxylase (AADC/DDC) to serotonin largely in peripheral tissues unless peripheral decarboxylation is pharmacologically inhibited.

Primary mechanisms (ranked):

  1. ↑ Serotonin biosynthesis via AADC/DDC conversion of 5-HTP to 5-HT (rate-limited by peripheral decarboxylation and transport into the CNS)
  2. ↑ Melatonin biosynthesis (indirect) by increasing serotonin substrate availability in pineal pathways (context-dependent)
  3. ↑/↔ Serotonergic GPCR signaling downstream of increased 5-HT tone (5-HT receptor subtype–dependent; includes cAMP/PKA and PLC/IP3/Ca²⁺ axes)
  4. ↔ Platelet and vascular serotonergic tone (serotonin uptake/release; hemostasis/vasoreactivity; context-dependent)
  5. Secondary redox modulation via (a) melatonin’s antioxidant signaling and (b) MAO-dependent 5-HT metabolism generating H₂O₂ (context-dependent)

Bioavailability / PK relevance: Oral PK is variable with prominent peripheral conversion to serotonin; historical human PK work reports multi-hour half-life and non-linear/variable exposure, with substantially altered disposition when co-administered with peripheral decarboxylase inhibitors (e.g., carbidopa) which reduces peripheral conversion and can increase CNS availability.

In-vitro vs systemic exposure relevance: Most mechanistic cellular studies that dose supraphysiologic 5-HTP/5-HT concentrations may exceed achievable free systemic levels with typical supplement dosing; many downstream effects are better interpreted as serotonergic tone (receptor-mediated) rather than direct intracellular target engagement by 5-HTP.

Clinical evidence status: Small-human evidence exists primarily in non-oncology indications (e.g., depression) but is limited by study quality/size; there is no credible clinical anticancer evidence base. Safety constraints and interaction risk (serotonergic drugs) are clinically material and often dominate translation decisions.

5-HTP (AD context) — In Alzheimer’s disease (AD), 5-HTP is mechanistically relevant only indirectly: it can increase serotonin availability (limited by peripheral decarboxylation) and may secondarily influence sleep/circadian biology via serotonin→melatonin pathways. The human evidence for 5-HTP in AD specifically is not established; available clinical work is better described as small studies in older adults (not necessarily AD) assessing cognition/mood, while broader AD-relevant biology is supported mainly by serotonergic-system and melatonin literature rather than 5-HTP intervention trials.

Primary mechanisms (ranked):

  1. ↑/↔ Central serotonergic tone (limited/variable CNS delivery; receptor subtype–dependent)
  2. ↑ Sleep/circadian support via serotonin→melatonin substrate effects (context-dependent)
  3. ↓/↔ Oxidative stress and mitochondrial stress (secondary; largely via melatonin-linked pathways; context-dependent)
  4. ↔ Neuroinflammation and synaptic function (secondary; downstream of serotonergic receptor signaling; context-dependent)
-Serotonin (from 5-HTP) is further converted into melatonin in the pineal gland, regulating sleep-wake cycles
- 5-HTP freely crosses the blood–brain barrier.
-Serotonin Does not cross the blood-brain barrier well if excessively converted in the periphery, which is why it's often taken with carbidopa (a peripheral decarboxylase inhibitor) in clinical contexts.
-Doses over ~300–400 mg/day should be taken cautiously and under supervision.
-Alzheimer’s Disease (AD) patients show marked reductions in serotonin levels and serotonergic neurons, especially in the raphe nuclei and hippocampus. 5-HTP could help restore serotonin levels in the brain, potentially supporting cognition and mood.
-5-HTP may help reduce microglial activation and inflammatory cytokines (e.g. TNF-α, IL-6), both elevated in AD.
-Serotonin and melatonin (a downstream product of 5-HTP) have antioxidant properties, which might help reduce ROS-induced neuronal damage in AD.
-Many AD patients are on SSRIs or cholinesterase inhibitors, which could interact with 5-HTP.

Alzheimer’s-relevant axes for 5-HTP (indirect)

Rank Pathway / Axis Modulation TSF Primary Effect Notes / Interpretation
1 Central serotonergic function ↑/↔ (delivery-dependent) P/R Potential symptom-domain effects (mood, sleep, behavior) AD biology includes serotonergic-system alterations; 5-HTP’s ability to shift CNS serotonin is variable due to peripheral decarboxylation and competing transport/handling.
2 Sleep–circadian axis ↑/↔ (context-dependent) R/G Sleep consolidation and circadian support Melatonin disruption is common in AD; 5-HTP may increase serotonin substrate for melatonin synthesis in some contexts, but this is indirect and not reliably demonstrated as an AD intervention.
3 Mitochondria and oxidative stress ↓/↔ (secondary) R/G Redox/mitochondrial stress buffering Mechanistic support is stronger for melatonin itself in neurodegeneration than for 5-HTP as a means to raise melatonin in AD.
4 Neuroinflammation and synaptic plasticity ↔ (secondary) G Downstream signaling shifts Serotonergic receptor signaling can modulate inflammatory tone and synaptic function, but directionality is receptor- and circuit-dependent; not a specific 5-HTP signature.
5 Clinical Translation Constraint — — Evidence gap + interaction + quality control No AD-specific efficacy base; serotonergic drug interactions matter in older adults; product quality/impurity concerns have been reported historically in some commercial 5-HTP lots.


Dose, Dosage: Click to Expand ⟱
Source:
Type:
Drug dosage vs efficacy, and actual dosage number of research papers.
Scientific Papers found: Click to Expand⟱
5307- 5-HTP,    5-Hydroxytryptophan toxicosis in dogs: 1989-1999
- Case Report, Nor, NA
*toxicity↝, *5HT↑, *Dose↝,
5306- 5-HTP,    Tryptophan-enriched diet or 5-hydroxytryptophan supplementation given in a randomized controlled trial impacts social cognition on a neural and behavioral level
- Trial, AD, NA
*cognitive↑, *Dose↝,
5303- 5-HTP,    5-HTP shows early promise for cognitive support and in seniors: Singapore study
- Trial, AD, NA
*cognitive↑, *Dose↝, *5HT↑,
5298- 5-HTP,    Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa
- Human, AD, NA
*BioAv↑, *Dose↝, *toxicity↝,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Synaptic & Neurotransmission ⓘ

5HT↑, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   Dose↝, 4,  

Functional Outcomes ⓘ

cognitive↑, 2,   toxicity↝, 2,  
Total Targets: 5

Scientific Paper Hit Count for: Dose, Dosage
4 5-Hydroxytryptophan
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:152  Target#:1114  State#:%  Dir#:4
  wNotes=0  sortOrder:rid,rpid

 

Home Page